Skip to main content

Advertisement

SpringerLink
Log in

Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aimed to evaluate whether normal serum matrix metalloproteinase-3 (MMP-3) levels can be used to predict clinical remission and normal physical function at a single time point when treating patients with rheumatoid arthritis (RA) in daily practice settings. Subjects were all 1321 RA patients who were treated at our hospital. The accuracy of serum MMP-3 levels was larger than those of C-reactive protein (CRP) levels for predicting clinical remission [Simplified Disease Activity Index (SDAI) ≤ 3.3], normal function [Disability Index of the Health Assessment Questionnaire (HAQ-DI) ≤ 0.5], and both in clinical remission and with normal function (clinical remission + normal function) using receiver operating characteristic curve analysis. Serum MMP-3 levels were significantly correlated with CRP levels [r 0.229 (men), r 0.476 (women)] using Pearson’s correlation coefficients. Among patients with normal CRP levels (n = 807), the percentage of patients in clinical remission, with normal function, and with clinical remission + normal function having normal serum MMP-3 levels was significantly higher than those with abnormal serum MMP-3 levels. In addition, among patients with the 28-point count Disease Activity Score-CRP (DAS28-CRP) remission (DAS28-CRP < 2.3), the percentage of patients in clinical remission, with normal function, and with clinical remission + normal function having normal serum MMP-3 levels was significantly higher than those with abnormal serum MMP-3 levels. Our findings suggest that normal serum MMP-3 levels, in combination with CRP levels or disease activity, are useful for predicting clinical remission and normal physical function in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094–1108

    Article  PubMed  Google Scholar 

  2. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA et al (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 38:1081–1087

    Article  CAS  Google Scholar 

  3. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A et al (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852–858

    Article  PubMed  CAS  Google Scholar 

  4. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D et al (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 42:83–88

    Article  CAS  Google Scholar 

  5. Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K et al (2007) Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 131:563–570

    PubMed  CAS  Google Scholar 

  6. Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62:33–43

    Article  PubMed  CAS  Google Scholar 

  7. Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R (2013) Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediat Inflamm 2013:183653

    Article  CAS  Google Scholar 

  8. Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN et al (2014) Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediat Inflamm 2014:179284

    Article  CAS  Google Scholar 

  9. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N et al (2007) Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 17:403–408

    Article  PubMed  CAS  Google Scholar 

  10. Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE (2016) Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis 19:377–384

    Article  PubMed  CAS  Google Scholar 

  11. Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I et al (2012) Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther 14:R30

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Ma JD, Wei XN, Zheng DH, Mo YQ, Chen LF, Zhang X et al (2015) Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther 17:289

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S et al (2016) MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther 18:55

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D et al (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888–893

    PubMed  CAS  Google Scholar 

  15. Kaneko A, Kida D, Saito K, Tsukamoto M, Sato T (2012) Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 32:3631–3637

    Article  PubMed  CAS  Google Scholar 

  16. Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M et al (2014) Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 24:17–25

    Article  PubMed  CAS  Google Scholar 

  17. Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T et al (2017) High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. Mod Rheumatol. https://doi.org/10.1080/14397595

  18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588

    Article  PubMed  Google Scholar 

  19. Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S (2012) Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis 71:534–540

    Article  PubMed  CAS  Google Scholar 

  20. Hattori Y, Kida D, Kaneko A (2017) Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Mod Rheumatol. https://doi.org/10.1080/14397595

  21. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Hospital Organization Nagoya Medical Center, Orthopaedic Surgery and Rheumatology, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan

    Yosuke Hattori, Daihei Kida & Atsushi Kaneko

Authors
  1. Yosuke Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daihei Kida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yosuke Hattori.

Ethics declarations

This study was approved by the ethics committee of our institute and was conducted from January through March 2013 in accordance with the Declaration of Helsinki. Patient anonymity was maintained during data collection, and security of personal information was strictly controlled. All patients gave their informed consent prior to their inclusion in the study.

Conflict of interest

Yosuke Hattori received grants from Pfizer and Janssen Pharma. Daihei Kida received grants from Towa Pharma Corporation and Chugai Pharma Corporation. Atsushi Kaneko received grants from Astellas Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hattori, Y., Kida, D. & Kaneko, A. Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clin Rheumatol 38, 181–187 (2019). https://doi.org/10.1007/s10067-017-3829-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3829-9

Keywords

Search

Navigation